News & Updates

In the final analysis of the phase III ICON8* study, a weekly dose-dense chemotherapy (CT) regimen comprising paclitaxel and carboplatin did not improve survival outcomes in women with epithelial ovarian cancer** compared with the standard first-line (1L) paclitaxel-carboplatin regimen given once every 3 weeks (Q3W).

Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.

Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.

Red cell transfusion at a high-volume tertiary hospital in Singapore has an incidence of 3.2 percent in a multiethnic obstetric population, according to a study. Anaemia during pregnancy is the most common reason for transfusion administration.

Adjuvant radiotherapy (RT) may be omitted in women with very low-risk breast cancer who have had breast conserving surgery (BCS) and have been receiving endocrine therapy, according to findings from the LUMINA study.

Diabetes mellitus and overweight or obesity appear to increase susceptibility to COVID-19 among pregnant women, with insulin-dependent gestational diabetes mellitus being associated with the disease, according to data from INTERCOVID.